文献速递瓣膜外科

淀粉样变性患者的主动脉瓣置换术

Aortic valve replacement in patients with amyloidosis.
PubMed 文献 · J Thorac Cardiovasc Surg · 2017-12-19

该研究回顾性分析了2000年5月至2017年2月间16例接受主动脉瓣置换术的淀粉样变性患者,其中11例(69%)为外科手术,5例为球囊扩张式经股动脉经导管主动脉瓣置入。术后30天内无手术相关卒中、新发透析或起搏器需求及死亡。经导管组中位住院时间1天(IQR 1-2天),外科组6天(IQR 6-8天)(P=0.002)。中位随访1.9年(IQR 1.2-4.8年)期间共4例死亡,均发生在术后1年以上。结论认为淀粉样变性患者行主动脉瓣置换术的手术并发症和死亡率风险低,经导管置入可缩短住院时间,1年生存率极好。

要点

  • 淀粉样变性患者行主动脉瓣置换术的围手术期卒中、透析、起搏器植入及30天内死亡均为零。
  • 经导管组中位住院时间1天(IQR 1-2天),外科组6天(IQR 6-8天)(P=0.002)。
  • 中位随访1.9年(IQR 1.2-4.8年)期间4例死亡,均发生于术后1年以上。

核心结论

  • 淀粉样变性患者行主动脉瓣置换术的手术并发症和死亡率风险低,经导管置入具有缩短住院时间的优势,1年生存率极好。

研究设计与样本

  • 回顾性综述了2000年5月至2017年2月间16例接受主动脉瓣置换术的淀粉样变性患者的记录。

主要发现

  • 队列包括11例男性(69%)和5例女性(31%),中位年龄76岁(IQR 71-82岁),STS预测死亡率为5.0%(IQR 2.4%-8.7%)。
  • 淀粉样变性类型为免疫球蛋白轻链型6例(38%)、年龄相关型6例(38%)、局限型4例(25%)。
  • 手术方式为外科主动脉瓣置换术11例(69%),球囊扩张式经股动脉经导管主动脉瓣置入5例。
  • 术后30天内无手术相关卒中、新发透析或起搏器需求及死亡。
  • 经导管组中位住院时间1天(IQR 1-2天),外科组6天(IQR 6-8天)(P=0.002)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Outcome data on aortic valve replacement in patients with amyloidosis are limited. To address this issue, we reviewed our experience of patients with amyloidosis who underwent aortic valve replacement. METHODS: We retrospectively reviewed the records of 16 patients with amyloidosis who underwent aortic valve replacement between May 2000 and February 2017. RESULTS: The cohort comprised 11 males (69%) and 5 females (31%). The median patient age was 76 years (interquartile range [IQR], 71-82 years), and Society of Thoracic Surgeons predicted rate of mortality was 5.0% (IQR, 2.4%-8.7%). Amyloidosis type was immunoglobulin light chain in 6 patients (38%), age-related in 6 (38%), and localized in 4 (25%). The operation was surgical aortic valve replacement in 11 patients (69%) and balloon-expandable transfemoral transcatheter aortic valve insertion in the other 5. There was no procedure-related stroke, need for new-onset dialysis or pacemaker, or death within 30 days of surgery. The median length of hospital stay was 1 day (IQR, 1-2 days) in the transcatheter valve insertion group and 6 days (IQR, 6-8 days) in the surgical group (P = .002). Follow-up was available for all patients at a median of 1.9 years (IQR, 1.2-4.8 years). During the follow-up period, there were 4 deaths, all occurring >1 year after surgery. CONCLUSIONS: Aortic valve replacement can be performed with low risk of operative morbidity and mortality in patients with amyloidosis. Transcatheter valve insertion has the advantage of reduced hospital length of stay. The 1-year survival is excellent.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Java AP, Greason KL, Dispenzieri A, et al. Aortic valve replacement in patients with amyloidosis. J Thorac Cardiovasc Surg. 2017. PMID: 29397971. doi:10.1016/j.jtcvs.2017.12.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。